Vimeo
LinkedIn
Instagram
Share |

FB News

Education has consistently ranked as one of the top philanthropic causes for wealthy families since the Global Family Office Report began collecting data on the field in 2014. Now, massive populations, increasing middle class income, and increasing spending on education in Asia is making the sector a compelling impact investment opportunity too.

Education has consistently ranked as one of the top philanthropic causes for wealthy families since the Global Family Office Report began collecting data on the field in 2014. Now massive populations, increasing middle class income, and increasing spending on education in Asia is making the sector a compelling impact investment opportunity too. 

In the past, children of ultra-wealthy families could expect a substantial part of their parent’s fortune to eventually pass to them. Now 21st century attitudes to wealth transfer are changing.

In the past, children of ultra-wealthy families could expect a substantial part of their parent’s fortune to eventually pass to them. Now 21st century attitudes to wealth transfer are changing. 

A dispute between Danish shipping giant Maersk and Los Angeles (LA) dockers over plans to automate port vehicles has highlighted the challenges legacy businesses face balancing innovation with the social cost wreaked by disruption.

A dispute between Danish shipping giant Maersk and Los Angeles (LA) dockers over plans to automate port vehicles has highlighted the challenges legacy businesses face balancing innovation with the social cost wreaked by disruption.

Foxconn tycoon Terry Gou announces his bid for Taiwan presidency, Desmarais scion hits back at banks over hidden fees, and Thailand’s richest man resigns as chairman of Charoen Pokphand Foods

Foxconn tycoon Terry Gou announces his bid for Taiwan presidency, Desmarais scion hits back at banks over hidden fees, and Thailand’s richest man resigns as chairman of Charoen Pokphand Foods.

How is one Chinese biotechnology group succeeding in supporting the earliest stage of new drug discovery when global pharmaceutical companies have given up? Dr Jun Mao, founder and chairwoman of Viva Ventures, explains how it leverages its in-house expertise to invest in hundreds of biotech startups in the $20 trillion global pharmaceutical and biotechnology market.

How is one Chinese biotechnology group succeeding in supporting the earliest stage of new drug discovery when global pharmaceutical companies have given up? Dr Jun Mao, founder and chairwoman of Viva Ventures, explains how it leverages its in-house expertise to invest in hundreds of biotech startups in the $20 trillion global pharmaceutical and biotechnology market. 

Click here >>
Close